86 related articles for article (PubMed ID: 2628237)
1. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
3. Bisantrene in relapsed and refractory acute myelogenous leukemia.
Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
5. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
[TBL] [Abstract][Full Text] [Related]
8. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
9. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
10. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.
Visani G; Rizzi S; Tosi P; Cenacchi A; Gamberi B; Lemoli RM; Papadopulu P; Tura S
Haematologica; 1990; 75(6):527-31. PubMed ID: 2098293
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
Vogler WR; Trulock PD
Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
[TBL] [Abstract][Full Text] [Related]
14. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
15. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
17. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
20. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]